Oric Pharmaceuticals (NASDAQ:ORIC) Issues Earnings Results, Misses Expectations By $0.05 EPS

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05), Zacks reports.

Oric Pharmaceuticals Stock Down 4.3%

NASDAQ:ORIC traded down $0.34 during trading hours on Monday, reaching $7.52. 1,196,157 shares of the stock were exchanged, compared to its average volume of 1,714,194. The firm has a 50 day simple moving average of $11.56 and a 200-day simple moving average of $11.01. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.68. The stock has a market capitalization of $779.47 million, a P/E ratio of -5.57 and a beta of 1.23.

Insider Activity at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 77,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $955,945.32. The trade was a 52.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on ORIC. Wedbush cut their price objective on Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 27th. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. HC Wainwright increased their target price on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Leerink Partners started coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, BTIG Research reiterated a “buy” rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a report on Wednesday, October 28th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Read Our Latest Research Report on Oric Pharmaceuticals

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

See Also

Earnings History for Oric Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.